The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies
10.3781/j.issn.1000-7431.2014.02.014
- Author:
Shi-Jie FAN
1
Author Information
1. Cancer Institute
- Publication Type:Journal Article
- Keywords:
Antineoplastic protocols;
Herpesvirus 4, human;
Neoplasms, second primary;
Targeted therapy;
Virus activation
- From:
Tumor
2014;34(2):180-186
- CountryChina
- Language:Chinese
-
Abstract:
The Epstein-Barr virus (EBV) has been demonstrated to be associated with several human tumors, including nasopharyngeal carcinoma (NPC), Burkitt's lymphoma (BL), post-transplant lymphoproliferative disease (PTLD), Hodgkin's lymphoma (HL), non-Hodgkin's lymphomas (NHL) and gastric cancer (GC). In most EBV-associated malignancies, the tumor cells contain the viral genome. This provides a unique opportunity to develop therapeutic strategies utilizing the viral genome of EBV as a potential drug target. This review focuses on different therapeutic strategies against EBV-associated malignancies, further discusses the possible therapeutic approach using drug-induced virus activation and its certain pathways. Copyright © 2014 by TUMOR.
